April 24, 2018 / 1:05 AM / 3 months ago

BRIEF-Astellas Pharma Submits NDA For Approval Of Gilteritinib

April 23 (Reuters) - Astellas Pharma Inc:

* ASTELLAS SUBMITS NEW DRUG APPLICATIONS FOR APPROVAL OF GILTERITINIB FOR THE TREATMENT OF FLT3MUT+ RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

* ASTELLAS PHARMA INC-SUBMITTED A NDA FOR APPROVAL OF GILTERITINIB IN SAME PATIENT POPULATION TO U.S. FOOD AND DRUG ADMINISTRATION ON MARCH 29, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below